Residency · Residency · Physical Medicine Rehabilitation
Guillain-Barre Syndrome: Acute and Post-Acute Rehabilitation
Introduction
Guillain-Barre syndrome (GBS) is an acute immune-mediated polyradiculoneuropathy characterized by rapidly progressive, ascending weakness and areflexia. Although most patients recover, approximately 20% have significant residual disability at one year. Rehabilitation is essential throughout the disease course, from acute ICU-based interventions through inpatient rehabilitation and long-term community reintegration. Physiatrists coordinate care across these phases.
Disease Overview
Subtypes
Acute inflammatory demyelinating polyradiculoneuropathy (AIDP): Most common in Western countries (85-90%). Acute motor axonal neuropathy (AMAN): More common in Asia; motor-predominant. Acute motor-sensory axonal neuropathy (AMSAN): Axonal variant with sensory involvement; worst prognosis. Miller Fisher syndrome: Ophthalmoplegia, ataxia, areflexia; anti-GQ1b antibodies.
| Subtype | Pathology | Epidemiology | Motor/Sensory | Prognosis | Antibody |
|---|---|---|---|---|---|
| AIDP | Demyelinating | Most common (West) | Mixed | Good | Variable |
| AMAN | Axonal (motor) | Common in Asia | Motor only | Moderate | Anti-GM1, anti-GD1a |
| AMSAN | Axonal (motor+sensory) | Less common | Mixed | Worst | Anti-GM1 |
| Miller Fisher | Demyelinating | 5% of GBS | Cranial nerves | Excellent | Anti-GQ1b |
Pathophysiology
Post-infectious autoimmune attack on peripheral nerves. Common antecedent infections: Campylobacter jejuni (30%), CMV, EBV, Zika, influenza. Molecular mimicry between microbial antigens and ganglioside components of nerve. AIDP: Segmental demyelination of nerve roots and peripheral nerves. AMAN/AMSAN: Antibody-mediated attack on axolemma at nodes of Ranvier.
Clinical Course
Ascending weakness reaching nadir within 2-4 weeks. Areflexia or hyporeflexia; sensory symptoms (paresthesias, pain) common. Autonomic dysfunction: Tachycardia, blood pressure lability, urinary retention. Respiratory failure requiring ventilation in 25-30%. Plateau phase followed by gradual recovery over weeks to months.
Acute Phase Rehabilitation
ICU and Acute Care Considerations
Respiratory monitoring: Serial FVC measurements; intubation if FVC <20 mL/kg or declining rapidly. DVT prophylaxis: Mechanical (SCDs) and pharmacological (LMWH). Pain management: Neuropathic pain in 50-90% of patients; gabapentin, pregabalin, or opioids for severe pain. Positioning to prevent contracture and pressure injury. Gentle range of motion exercises (avoid overstretching weakened muscles).
Medical Treatment
Intravenous immunoglobulin (IVIG): 0.4 g/kg/day for 5 days; initiated within 2 weeks of symptom onset. Plasma exchange (PLEX): Alternative to IVIG; 5 exchanges over 2 weeks. Corticosteroids are NOT effective and should not be used. IVIG and PLEX equally effective; should not be combined sequentially.
Early Rehabilitation Interventions
Physical therapy: Bed mobility, positioning, gentle ROM, respiratory exercises. Occupational therapy: Upper extremity positioning, basic ADL support. Speech therapy if bulbar involvement (dysphagia screening). Psychological support for anxiety and adjustment. Family education about disease course and expected recovery.
Inpatient Rehabilitation
Admission Criteria
Functional deficits sufficient to require multidisciplinary rehabilitation. Medical stability (off ventilator or stable on NIV; stable autonomic function). Ability to tolerate 3 hours of therapy per day (or 15 hours/week for IRF). Clear rehabilitation goals with reasonable expectation of functional gain.
Rehabilitation Program
Progressive strengthening: Begin with gravity-eliminated exercises; advance as tolerated. Aerobic conditioning: Stationary cycling, aquatic therapy when appropriate. Avoid overwork weakness: Monitor for post-exercise fatigue lasting >24 hours. Balance and gait training: Progress from parallel bars to assistive devices to independent ambulation.
ADL training with adaptive equipment as needed. Orthotic assessment: AFOs for persistent foot drop; wrist splints for hand weakness.
Functional Recovery Trajectory
AIDP patients: Majority begin recovery within 2-4 weeks after nadir. Axonal variants: Slower recovery; may take 6-18 months for meaningful improvement. Independent ambulation achieved by 60-80% at 1 year. Residual deficits: Fatigue (80%), distal weakness, sensory loss, pain.
Prognostic Factors
Poor prognostic indicators: Age >60 years. Rapid onset to nadir (<7 days). Need for mechanical ventilation.
Axonal variant on electrodiagnostics. Low compound muscle action potential (CMAP) amplitudes. Preceding Campylobacter jejuni infection. Erasmus GBS Outcome Score (EGOS): Predicts ability to walk independently at 6 months.
Post-Acute and Community Rehabilitation
Outpatient Therapy
Continued progressive strengthening and endurance training. Community integration skills: Stairs, uneven surfaces, community mobility. Return to work and driving readiness assessment. Energy conservation and fatigue management strategies.
Long-Term Sequelae
Fatigue: Most common long-term complaint; may persist for years. Neuropathic pain: Chronic in 30-40%; may require long-term pharmacotherapy. Residual distal weakness: Hand intrinsic and ankle dorsiflexor weakness most common. Psychological impact: Depression, anxiety, PTSD (especially post-ICU patients). Reduced exercise tolerance and deconditioning.
Exercise in Recovery
Aerobic exercise improves fitness and reduces fatigue in recovered GBS patients. Moderate-intensity cycling or walking programs recommended. Resistance training at submaximal loads; avoid eccentric overload. Monitor for overwork weakness and adjust intensity accordingly. Long-term exercise adherence improves functional outcomes.
Special Considerations
Autonomic Dysfunction
Blood pressure lability may complicate early mobilization (orthostatic hypotension). Cardiac arrhythmias: Continuous monitoring during acute phase. Bladder dysfunction: Intermittent catheterization protocol. Bowel management: Constipation common; bowel program as needed.
Pediatric GBS
Generally better prognosis than adults. Play-based therapy and family-centered rehabilitation. School reintegration planning. Most children achieve full recovery, though residual fatigue is common.
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Suspected if progression continues beyond 8 weeks or relapse occurs. Requires ongoing immunomodulatory treatment (IVIG, corticosteroids, plasma exchange). Rehabilitation approach similar but adjusted for chronic/relapsing course.
Key Clinical Pearls
- Respiratory failure occurs in 25-30% of GBS patients; serial FVC monitoring is mandatory, with intubation considered when FVC falls below 20 mL/kg or shows a rapidly declining trajectory. 2. Overwork weakness is a genuine risk in GBS rehabilitation; exercise intensity should be carefully titrated, and post-exercise fatigue lasting more than 24 hours indicates the need to reduce activity level. 3. Axonal variants (AMAN, AMSAN) have slower and often incomplete recovery compared to AIDP, which has important implications for rehabilitation goal-setting and prognostication. 4. Fatigue is the most common long-term sequela of GBS, persisting in up to 80% of patients even after motor recovery, and should be addressed with energy conservation strategies and graded exercise programs. .
References
- Hughes RAC, et al. "Guillain-Barre Syndrome." Lancet. 2005;366(9497):1653-1666.
- Khan F, et al. "Rehabilitation After Guillain-Barre Syndrome: A Systematic Review." J Neurol Neurosurg Psychiatry. 2011;82(3):352-358.
- Walgaard C, et al. "Prediction of Respiratory Insufficiency in Guillain-Barre Syndrome." Ann Neurol. 2010;67(6):781-787.
- Garssen MPJ, et al. "Physical Training and Fatigue, Fitness, and Quality of Life in Guillain-Barre Syndrome and CIDP." Neurology. 2004;63(12):2393-2395.